The peripheral blood lymphocyte signatures forecast therapeutic efficacy in papillary thyroid cancer patients undergoing radioactive iodine therapy | Synapse
March 3, 2026
The peripheral blood lymphocyte signatures forecast therapeutic efficacy in papillary thyroid cancer patients undergoing radioactive iodine therapy
Puntos clave
Therapeutic efficacy is forecasted using peripheral blood lymphocyte signatures, indicating a promising predictor for patient outcomes.
Key evidence shows a significant correlation between lymphocyte signatures and therapy response in papillary thyroid cancer patients.
Observational analysis reveals the potential of lymphocyte signatures to guide radioactive iodine therapy effectiveness in treating papillary thyroid cancer.
Findings support the use of lymphocyte signatures for personalized approaches in cancer therapy, calling for further validation across diverse populations.